Acorda Therapeutics, Inc. : Pharmaceuticals and Healthcare - Company Profile, SWOT & Financial Report 4/22/2013 \| published by: iCD Research ... information and data about the company and its operations. The profile contains a company overview, key facts,major products and services, swot analysis, business description, company history, key competitors, financial analysis, recent developments, key employees as ... \| read more...	$125.00
Celgene Corporation : Pharmaceuticals and Healthcare - Company Profile, SWOT & Financial Report 4/21/2013 \| published by: iCD Research ... data about the company and its operations. The profile contains a company overview, key facts,major products and services, swot analysis, business description, company history, financial analysis, mergers & acquisitions, recent developments, key employees, company locations ... \| read more...	$125.00
Global Chiral Technology Market 2012-2016 4/19/2013 \| published by: Infiniti Research Limited ... growth is favorable government regulations for chiral technology. The Global Chiral Technology market has also been witnessing increasing reliance on generic approaches. However, the slow commercialization of chiral technology-based products could pose a challenge to ... \| read more...	$2,000.00
Global Proteomics Market 2012-2016 4/19/2013 \| published by: Infiniti Research Limited ... the increasing demand for personalized medicines. The Global Proteomics market has also been witnessing a shift from genomics to proteomics. However, the intense competition among vendors could pose a challenge to the growth of this ... \| read more...	$2,000.00
Starches and Starch Products in Spain: ISIC 1532 4/18/2013 \| published by: Euromonitor International ... the Starches and Starch Products market at a national level. It provides the latest retail sales data, allowing you to identify the sectors driving growth. It identifies the leading companies, the leading brands and offers ... \| read more...	$600.00
Kuros Biosurgery AG - Product Pipeline Analysis, 2013 Update 4/17/2013 \| published by: GlobalData ... Technology and University of Zurich. Kuros's product pipeline consists of wound care products, trauma care products and spinal products. The company’s product portfolio consists of fusion proteins of naturally occurring bioactive factors that are covalently ... \| read more...	$750.00
Myriad Genetics, Inc. (MYGN) - Product Pipeline Analysis, 2013 Update 4/17/2013 \| published by: GlobalData ... predictive medicine, prognostic medicine and personalized medicine products in the areas of oncology and CNS related disorders. Its commercial molecular diagnostic tests comprise BRACAnalysis, COLARIS, MELARIS, PANEXIA, OnDose, COLARIS AP, PREZEON, TheraGuide, TruCulture, DiscoveryMAP, Prolaris ... \| read more...	$750.00
Interleukin Genetics, Inc. (ILIU) - Product Pipeline Analysis, 2013 Update 4/17/2013 \| published by: GlobalData ... tests includes genetic tests in weight management, heart health, bone health and nutritional needs. PST Genetic Susceptibility Test is the genetic test that helps in identifying interleukin 1 gene that has variations leading to the ... \| read more...	$750.00
Genomic Health, Inc. (GHDX) - Product Pipeline Analysis, 2013 Update 4/17/2013 \| published by: GlobalData ... consists of Oncotype DX breast cancer test and Oncotype DX colon cancer test. Its product pipeline helps diagnose potential breast cancer populations; stage II and III colon cancer; prostate cancer; renal cancer; non-small cell lung ... \| read more...	$750.00
Bioheart, Inc. (BHRT) - Product Pipeline Analysis, 2013 Update 4/17/2013 \| published by: GlobalData ... multiple cell therapies in various stages of development that repair damaged hearts. The company's MyoCell, MyoCell SDF-1, and MyoCath therapies improve cardiac function of a chronic heart failure patient. MyoCell SDF-1 is a gene-modified myoblast ... \| read more...	$750.00
InterGenetics Incorporated - Product Pipeline Analysis, 2013 Update 4/17/2013 \| published by: GlobalData ... treatment of breast cancer effective only in the subset of women with tumors tested to have the molecular biology vulnerable to the treatment. Its services include research identification of a particular gene that is now ... \| read more...	$750.00
2013 Analysis of the Pap Smear/HPV Testing Market: US, Europe (France, Germany, Italy, Spain, UK), Japan-- Emerging Opportunities, Country Forecasts, Innovative Technologies, and Competitive Landscape 4/17/2013 \| published by: Venture Planning Group ... the disease. During the next ten years, the worldwide cancer testing market is promising to be an exciting, dynamic and rapidly expanding field. Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting ... \| read more...	$4,350.00
3SBio Inc. (SSRX) - Financial and Strategic SWOT Analysis Review 4/16/2013 \| published by: GlobalData ... candidates to address large markets with significant unmet medical needs in oncology, nephrology, supportive cancer care, infectious diseases and inflammation. Its product pipeline include EPIAO, TPIAO, INTEFEN, INLEUSIN and IV Iron Sucrose. The company conducts ... \| read more...	$125.00
Acorda Therapeutics, Inc. (ACOR) - Financial and Strategic SWOT Analysis Review 4/16/2013 \| published by: GlobalData ... (MS), spinal cord injury (SCI), and other disorders of the nervous system. The company markets two products, namely, Ampyra, to improve walking in patients with MS and Zanaflex, to manage spasticity. Acorda Therapeutics, Inc. Key ... \| read more...	$125.00
InterMune, Inc. (ITMN) - Financial and Strategic SWOT Analysis Review 4/16/2013 \| published by: GlobalData ... active, small molecule compound, indicated for the treatment of adults with mild to moderate idiopathic pulmonary fibrosis. Pirfenidone is marketed in Germany, Austria, Belgium, Denmark, France, Iceland, Luxembourg, Norway and Sweden. It is also commercialized ... \| read more...	$125.00
Lixte Biotechnology Holdings, Inc. (LIXT) - Financial and Strategic SWOT Analysis Review 4/16/2013 \| published by: GlobalData ... abnormalities of human cancers, neurodegenerative diseases, glioblastoma multiforme, neuroblastoma and medulloblastoma and other cancers. The company currently develops two classes of drugs, LB-100 and LB-200, for which the company holds patent rights. Lixte Biotechnology Holdings, ... \| read more...	$125.00
Novartis AG (NOVN) - Financial and Strategic SWOT Analysis Review 4/9/2013 \| published by: GlobalData ... health market. The company's product portfolio includes innovative medicines, preventive vaccines and diagnostic tools, generic pharmaceuticals and consumer health products focused on oncology, neurosciences, ophthalmology, respiratory, immunology and infections. The company operates its business through ... \| read more...	$125.00
Interleukin Genetics, Inc. (ILIU) - Financial and Strategic SWOT Analysis Review 4/9/2013 \| published by: GlobalData ... tests includes genetic tests in weight management, heart health, bone health and nutritional needs. PST Genetic Susceptibility Test is the genetic test that helps in identifying interleukin 1 gene that has variations leading to the ... \| read more...	$125.00
Lpath, Inc. (LPTN) - Financial and Strategic SWOT Analysis Review 4/9/2013 \| published by: GlobalData ... retinal diseases; ASONEP indicated for various types of cancer; Lpathomab indicated for fibrosis, spinal cord injury, traumatic brain injury, neuropathic pain and cancer; and Nextomabs indicated for inflammation and cancer. It has a patent portfolio ... \| read more...	$125.00
Oncolytics Biotech Inc. (ONC) - Financial and Strategic SWOT Analysis Review 4/9/2013 \| published by: GlobalData ... is focused on identifying the oncolytic capability of the human reovirus to treat patients suffering from cancer that have not been successfully treated with conventional therapeutics. The company's proprietary formulation of the human reovirus, Reolysin, ... \| read more...	$125.00
Sarepta Therapeutics, Inc. (SRPT) - Financial and Strategic SWOT Analysis Review 4/9/2013 \| published by: GlobalData ... phosphorodiamidate morpholino oligomer (PMO) technology platforms. The product candidates for the treatment of Duchenne muscular dystrophy include Eteplirsen is in Phase II of clinical development and AVI-7228 (an oligomer of AVI-6003 being developed for treating ... \| read more...	$125.00
Bioheart, Inc. (BHRT) - Financial and Strategic SWOT Analysis Review 4/9/2013 \| published by: GlobalData ... multiple cell therapies in various stages of development that repair damaged hearts. The company's MyoCell, MyoCell SDF-1, and MyoCath therapies improve cardiac function of a chronic heart failure patient. MyoCell SDF-1 is a gene-modified myoblast ... \| read more...	$125.00
SkinEthic Laboratories - Strategic SWOT Analysis Review 4/9/2013 \| published by: GlobalData ... and efficacy tests for decision making during research and development phases. The company’s product line includes reconstructed human epidermis; reconstructed human epidermis with melanocytes; and reconstructed human corneal epithelium and reconstructed human mucosa such as ... \| read more...	$125.00
Starches and Starch Products in Canada: ISIC 1532 4/9/2013 \| published by: Euromonitor International ... the Starches and Starch Products market at a national level. It provides the latest retail sales data, allowing you to identify the sectors driving growth. It identifies the leading companies, the leading brands and offers ... \| read more...	$600.00
Biomaterials China News 1304 4/8/2013 \| published by: CCM International Limited ... a proposal about strengthening the development of green agriculture put forward by the Jiu San (Sept. 3) Society was selected as the No. 1 proposal of CPPCC, and biodegradable agricultural film may benefit from it. ... \| read more...	$2,511.00

< prev 1 2 3 4 5 6 7 8 9 10 next >